AzurRx BioPharma, Inc. - FORM 8-K - EX-23.1 - CONSENTS OF EXPERTS AND COUNSEL - September 13, 2021

Attached files

file filename
EX-99.6 - THE UNAUDITED PRO FORMA CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - AzurRx BioPharma, Inc.azrx_ex996.htm
EX-99.5 - THE UNAUDITED INTERIM FINANCIAL STATEMENTS OF FIRST WAVE BIO - AzurRx BioPharma, Inc.azrx_ex995.htm
EX-99.4 - THE AUDITED FINANCIAL STATEMENTS OF FIRST WAVE BIO - AzurRx BioPharma, Inc.azrx_ex994.htm
EX-99.3 - DESCRIPTION OF BUSINESS AND RISK FACTOR UPDATE - AzurRx BioPharma, Inc.azrx_ex993.htm
EX-99.2 - CORPORATE PRESENTATION - AzurRx BioPharma, Inc.azrx_ex992.htm
EX-99.1 - PRESS RELEASE - AzurRx BioPharma, Inc.azrx_ex991.htm
EX-2.1 - AGREEMENT AND PLAN OF MERGER - AzurRx BioPharma, Inc.azrx_ex21.htm
8-K - CURRENT REPORT - AzurRx BioPharma, Inc.azrx_8k.htm

EXHIBIT 23.1

 

CONSENT OF INDEPENDENT PUBLIC ACCOUNTING FIRM

 

We consent to the incorporation by reference in the Registration Statements on Form S-1 (File Nos. 333-235768 and 333-252087), Form S-8 (File No. 333-220781) and Form S-3 (File Nos. 333-226065, 333-231035, 333-231954, 333-240129, 333-252623 and 333-256476) of AzurRx BioPharma, Inc. of our report dated August 30, 2021 with respect to the balance sheets of First Wave Bio, Inc. as of December 31, 2020 and 2019 and the related statements of operations, stockholders’ equity (deficit), and cash flows, for the years then ended, which report appears in the Form 8-K of AzurRx BioPharma, Inc. dated September 13, 2021.

 

/s/ Plante & Moran, PLLC

 

Southfield, Michigan

Consent Date

AzurRx BioPharma, Inc. Reports